In the Media

Vidac Pharma - Technical report causes a stir

Vidac Pharma, a listed company in the clinical development phase, offers an exciting and promising prospect. Vidac Pharma's latest product, VDA-1275, is at the center of interest following a technical report. This innovative drug candidate for the treatment of solid tumors has achieved impressive results in preclinical studies. As a monotherapy, VD...

The new technology being developed by Vidac Pharma, a company founded in 2012 and led by Prof. Max Herzberg, one of the founding fathers of the Israeli life sciences industry, is groundbreaking. Vidac Pharma is researching drugs designed to help cancer patients by reversing the abnormal metabolism of cancer cells, thereby stopping the proliferation...

A mega rally could start here, at least according to analysts who analyzed the recently published results of tests with next-generation drug candidates in human and murine tumour models. According to the analysis, Sphene Capital sees a price target of no less than EUR 4.90 for Vidac Pharma, representing a potential upside of 1,662% from the current...

Among the biotech small-cap stocks, Vidac Pharma has recently made headlines. The British-Israeli company has recently published promising results of its studies with the promising compound VDA-1275 in several mouse and human cellular organoid models of solid tumours in a scientific article. The paper has been submitted for independent peer review...

With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking breakthrough. The reason for this is the discovery of a particular enzyme and its mode of action. At the same time...

We have reported several times on Vidac Pharma plc in recent weeks. The interest in the share is enormous for a penny stock, with over 200,000 shares changing hands at times. The Company has just announced that the US Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent application to protect a group of molecules. These...

The biopharmaceutical company Vidac Pharma, which specializes in developing innovative cancer treatments, has recently achieved a significant milestone. On June 3, the Company was awarded a key patent for its group of molecules by the US Patent and Trademark Office. These molecules can release the enzyme hexokinase-2 (HK2) from the mitochondrial VD...

FinanzNachrichten provides financial news and updates specifically related to Vidac Pharma Holdings PLC. It covers the company's stock performance, recent financial news, market analysis, and any significant corporate announcements. The page serves as a resource for investors and analysts looking to stay informed about Vidac Pharma's financial stat...

Vidac Pharma has not yet broken out of its sideways movement, but this is likely only a matter of time. The London-based biotech company is making good progress in cancer research and has been traded as a takeover candidate, especially since Genmab's billion-dollar acquisition of ProfoundBio. Vidac Pharma's innovative approach has the potential to...

There is hope on the horizon for biotech investors, according to news | financial, even if a rally in the Nasdaq Biotech Index late last year did
not persist in 2024. Tough refinancing conditions have been holding the market back, according to the German website.

But if an interest rate cut materializes over the summer, the outlook would look a lot b...

Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the canc...

Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for personalized medicines and the rapid development of new forms of therapy through technological progress a...

The biopharmaceutical company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker symbol: T9G), which is based in Israel and the UK, received notification of approval for its drug candidate VDA-1275 from the Japanese Patent Office at the end of March 2024. This has already shown several promising effects in the preclinical phase and has been us...

UK and Israel-based Vidac Pharma plc (STU: T9G, WKN: A3DTUQ, ISIN: GB00BM9XQ619) is another clinical-stage biopharmaceutical company developing first-in-class oncology and oncodermatology therapies. Its breakthrough new technology, which corrects a common feature of all cancer cells, holds the promise of a fundamentally new way of treating cancer a...